@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 A healthy 56-year-old man presents with neck swelling persisting after 2 weeks of antibiotics. No congenital anamoly. PPD negative. #TumorBoardTuesday
What would you do next ? @marklewismd @StephenVLiu
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo He was sequentially treated with six multi-kinase inhibitor regimens: sorafenib [best response of progressive disease (PD)], vandetanib [stable disease (SD)], cabozantinib (SD), MGCD-516 (PD), RXDX-105 [partial response (PR)], & vandetanib+ everolimus (PD).
#TumorBoardTuesday

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Vivek Subbiah, MD

Vivek Subbiah, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VivekSubbiah

11 Feb
1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published as Rapid impact paper @oalhalabimd et al
@MCR_AACR @AACR @CancerMedMDA #GU21 @ASCO @OncoAlert
#bcsm bit.ly/3d25A1U
2/6 Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies @OncoAlert @MCR_AACR @oalhalabimd . #bcsm bit.ly/3d25A1U
3/6 Patients' tumors or circulating tumor DNA were analyzed by NGS. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%. #GU21 @MCR_AACR @oalhalabimd #bcsm bit.ly/3d25A1U
Read 6 tweets
24 Jan
1/10 COVID19 & Cancer👉Several studies now provide insights into the enigma surrounding the determinants of COVID-19 & cancer 👉A global effort to understand the riddles of COVID-19 and cancer @NatureCancer @COVID19nCCC @OncoAlert nature.com/articles/s4301…
2/10 Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort @NatureCancer @barlesi @AlbigesL @FAndreMD @jsoriamd @oncoalert nature.com/articles/s4301…
3/10 SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer @NatureCancer @OncoAlert nature.com/articles/s4301…
Read 10 tweets
31 Dec 20
🚨⭐️ By popular demand 👉The Top 10 clinical publications in Oncology in 2020 (In no particular order). Some important papers bundled + Additional 5 more papers representing major advances in the field @OncoAlert
1. Pembrolizumab led to significantly longer progression-free survival vs chemotherapy as first-line therapy for MSI-H–dMMR metastatic colorectal cancer 👉Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer @NEJM @agrothey nejm.org/doi/full/10.10…
2. Most children with neurofibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shrinkage and clinical benefit from selumetinib 👉Selumetinib in Children with Inoperable Plexiform Neurofibromas @NEJM nejm.org/doi/full/10.10…
Read 16 tweets
9 Jan 20
#1 HOT OFF THE PRESS @CellCellPress Introducing MASTER OBSERVATIONAL TRIAL (MOT): A NEW class of Master Protocol to Advance #PrecisionMedicine cell.com/cell/fulltext/… MOT hybridizes power of molecularly based master interventional protocols with the breadth of #realworlddata
# 2The Master Observational Trial (MOT)-->Patients are broadly accepted into the trial along with diagnosis + staging info. Biomarker testing results (both positive and negative) are collected & classified using methods shown in Figures 1A and 1B.
# 3High-level outcomes are collected in connection with each line of therapy. All of the information is tied together in a prospective observational registry using standardized reporting methods and metrics. cell.com/cell/fulltext/…
Read 16 tweets
9 Sep 19
Presenting the GLOBAL Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of Selpercatinib #LOXO-292 in Patients with #RET + NSCLC !Thank you to all the patients and caregivers ! Huge win for RET + #NSCLC patients #precisionmedicine #LCSM #endcancer Image
RET Fusions are bonafide #lung cancer drivers #LSCM Image
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(